Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD)
Latest Information Update: 20 Jan 2025
At a glance
- Drugs CORT 108297 (Primary)
- Indications Post-traumatic stress disorders
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 14 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 19 Oct 2022 Status changed from not yet recruiting to recruiting.